JPWO2019222663A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019222663A5 JPWO2019222663A5 JP2020564394A JP2020564394A JPWO2019222663A5 JP WO2019222663 A5 JPWO2019222663 A5 JP WO2019222663A5 JP 2020564394 A JP2020564394 A JP 2020564394A JP 2020564394 A JP2020564394 A JP 2020564394A JP WO2019222663 A5 JPWO2019222663 A5 JP WO2019222663A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- binding molecule
- binding
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 68
- 102000036639 antigens Human genes 0.000 claims description 68
- 108091007433 antigens Proteins 0.000 claims description 68
- 239000012634 fragment Substances 0.000 claims description 20
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000057640 human CD63 Human genes 0.000 claims description 10
- 102100025222 CD63 antigen Human genes 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000013607 AAV vector Substances 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000001808 exosome Anatomy 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012083 RIPA buffer Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673098P | 2018-05-17 | 2018-05-17 | |
| US62/673,098 | 2018-05-17 | ||
| US201862681563P | 2018-06-06 | 2018-06-06 | |
| US62/681,563 | 2018-06-06 | ||
| US201862777592P | 2018-12-10 | 2018-12-10 | |
| US62/777,592 | 2018-12-10 | ||
| PCT/US2019/032922 WO2019222663A1 (en) | 2018-05-17 | 2019-05-17 | Anti-cd63 antibodies, conjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524231A JP2021524231A (ja) | 2021-09-13 |
| JPWO2019222663A5 true JPWO2019222663A5 (pt) | 2022-05-12 |
| JP7477462B2 JP7477462B2 (ja) | 2024-05-01 |
Family
ID=66691071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564394A Active JP7477462B2 (ja) | 2018-05-17 | 2019-05-17 | 抗ｃｄ６３抗体、コンジュゲート、及び、それらの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210079109A1 (pt) |
| EP (1) | EP3793591A1 (pt) |
| JP (1) | JP7477462B2 (pt) |
| KR (1) | KR20210010916A (pt) |
| CN (1) | CN112135624A (pt) |
| AU (1) | AU2019269685A1 (pt) |
| BR (1) | BR112020023145A2 (pt) |
| CA (1) | CA3100021A1 (pt) |
| CL (2) | CL2020002965A1 (pt) |
| CO (1) | CO2020015052A2 (pt) |
| MA (1) | MA52626A (pt) |
| MX (1) | MX2020012350A (pt) |
| PH (1) | PH12020551955A1 (pt) |
| SG (1) | SG11202011232VA (pt) |
| WO (1) | WO2019222663A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150620A1 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Crispr-mediated transgene insertion in neonatal cells |
| WO2023194501A1 (en) * | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
| CN116041520B (zh) * | 2022-12-28 | 2023-09-22 | 武汉爱博泰克生物科技有限公司 | 针对Human CD63的兔单克隆抗体及其制备方法和应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| EP1086223B1 (en) | 1998-06-01 | 2009-07-29 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| DK2167963T3 (da) | 2007-05-23 | 2019-06-24 | Ventana Med Syst Inc | Polymerbærere til immunhistokemi og in situ-hybridisering |
| KR20100137585A (ko) | 2008-04-30 | 2010-12-30 | 이뮤노젠 아이엔씨 | 강력한 복합체 및 친수성 링커 |
| JP5622117B2 (ja) | 2008-07-21 | 2014-11-12 | ポリテリクスリミテッド | 生体分子を接合するための新規な試薬及び方法 |
| EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| JP5954789B2 (ja) | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| PT2505654T (pt) | 2010-02-08 | 2016-11-18 | Regeneron Pharma | Rato de cadeia leve comum |
| PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| ES2748832T5 (es) | 2011-02-25 | 2023-06-08 | Regeneron Pharma | Ratones ADAM6 |
| CN103702996A (zh) | 2011-05-27 | 2014-04-02 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP3388435B1 (en) | 2011-10-14 | 2023-05-03 | Seagen Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EA036202B1 (ru) | 2011-10-14 | 2020-10-14 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| EA029046B1 (ru) | 2011-10-14 | 2018-02-28 | Медимьюн Лимитед | Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| KR102081657B1 (ko) | 2011-12-20 | 2020-02-26 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| EP3421488A3 (en) * | 2012-03-14 | 2019-04-17 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| SI2911699T1 (en) | 2012-10-23 | 2018-04-30 | Synaffix B.V. | MODIFIED AGAINST, PROTITELO-KONJUGAT AND PROCESS FOR THEIR PREPARATION |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AU2014218854B2 (en) * | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| CN105188766B (zh) | 2013-03-15 | 2019-07-12 | 瑞泽恩制药公司 | 生物活性分子、其偶联物及治疗用途 |
| JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| JP6948950B2 (ja) | 2015-03-27 | 2021-10-13 | レゲネロン ファーマシューティカルス，インコーポレーテッド | メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 |
| EP3408271B1 (en) | 2016-01-25 | 2023-01-11 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| KR20180104148A (ko) * | 2016-02-05 | 2018-09-19 | 젠맵 에이/에스 | 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자 |
| BR112019025888A2 (pt) * | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
-
2019
- 2019-05-17 AU AU2019269685A patent/AU2019269685A1/en active Pending
- 2019-05-17 SG SG11202011232VA patent/SG11202011232VA/en unknown
- 2019-05-17 JP JP2020564394A patent/JP7477462B2/ja active Active
- 2019-05-17 US US17/056,301 patent/US20210079109A1/en active Pending
- 2019-05-17 MA MA052626A patent/MA52626A/fr unknown
- 2019-05-17 CN CN201980032750.8A patent/CN112135624A/zh active Pending
- 2019-05-17 MX MX2020012350A patent/MX2020012350A/es unknown
- 2019-05-17 BR BR112020023145-2A patent/BR112020023145A2/pt unknown
- 2019-05-17 WO PCT/US2019/032922 patent/WO2019222663A1/en active Application Filing
- 2019-05-17 CA CA3100021A patent/CA3100021A1/en active Pending
- 2019-05-17 EP EP19728288.2A patent/EP3793591A1/en active Pending
- 2019-05-17 KR KR1020207036307A patent/KR20210010916A/ko active Search and Examination
-
2020
- 2020-11-16 CL CL2020002965A patent/CL2020002965A1/es unknown
- 2020-11-16 PH PH12020551955A patent/PH12020551955A1/en unknown
- 2020-11-30 CO CONC2020/0015052A patent/CO2020015052A2/es unknown
-
2022
- 2022-01-13 CL CL2022000094A patent/CL2022000094A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113564150A (zh) | 半胱氨酸蛋白酶 | |
| CN117467017A (zh) | 双特异性四价抗体及其制备和使用方法 | |
| IE902770A1 (en) | Methods and compositions for ameliorating the symptoms of¹sepsis | |
| WO2022095926A1 (zh) | 靶向于白介素36r的抗体及其制备方法和应用 | |
| Freches et al. | PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’antibody fragment after pulmonary delivery in three different species | |
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| WO2007119447A1 (ja) | 関節リウマチの処置剤 | |
| JP2618618B2 (ja) | 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体 | |
| JP2021501213A5 (pt) | ||
| JPWO2019222663A5 (pt) | ||
| WO2018223958A1 (zh) | 一种含c-Met抗体药物偶联物的药物组合物及其用途 | |
| Moricoli et al. | Blocking monocyte transmigration in in vitro system by a human antibody scFv anti-CD99. Efficient large scale purification from periplasmic inclusion bodies in E. coli expression system | |
| KR20170082631A (ko) | 뇌졸중의 치료 또는 예방 방법 | |
| Hattori et al. | Successful acquisition of a neutralizing monoclonal antibody against a novel neutrophil-activating peptide, mitocryptide-1 | |
| RU2380116C2 (ru) | Лечение микозов | |
| CN113698478A (zh) | 抗α-溶血素的抗体及其稳定制剂 | |
| JP2022528230A (ja) | Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用 | |
| JPH03103175A (ja) | ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤 | |
| US20240067716A1 (en) | Ionic liquid formulations for treating inflammatory and autoimmune diseases | |
| US20170342136A1 (en) | Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases | |
| RU2769223C1 (ru) | Средство и способ терапии и экстренной профилактики заболеваний, вызываемых вирусом SARS-CoV-2 на основе рекомбинантного антитела и гуманизированного моноклонального антитела | |
| WO2023109962A1 (zh) | 结合人cd73的抗体、其制备方法和用途 | |
| WO2020233695A1 (zh) | 抗乙肝病毒新型抗体及其用途 | |
| RU2779430C2 (ru) | Фармацевтическая композиция, содержащая антитело к sost, и ее применения | |
| JPH04262792A (ja) | 蛋白質の精製法 |